Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
68Ga-FAPI-46 PET/CT in Pancreatic and Biliary Cancers
NCT07478523Phase 2Recruiting
- Sponsor
- Centre Hospitalier Universitaire de Bordeaux
- Start
- Apr 2026
- Primary completion
- Mar 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of 68Ga FAPI-46 in pancreatic adenocarcinoma (PDAC) and cholangiocarcinoma (CCA), sponsored by Centre Hospitalier Universitaire de Bordeaux. Primary endpoint: Proportion of patients with change in TNM classification or therapeutic management at Day 0. Started Apr 2026; status: recruiting.
02
Drugs
68Ga FAPI-46
03
Conditions
pancreatic adenocarcinoma (PDAC)cholangiocarcinoma (CCA)
Beyond the preview
Go deeper on NCT07478523.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07478523.